|

Tolecizumab (PCSK9 Inhibitor) Clinical Trials

1 actively recruiting trial

Also known as: CapeOX Regimen (Oxaliplatin + Capecitabine), Sintilimab (PD-1 Inhibitor)

Pipeline

Phase 2: 1

Top Sponsors

  • Daping Hospital and the Research Institute of Surgery of the Third Military Medical University1

Indications

  • Colon Adenocarcinoma1
  • Cancer1

Other1 trial

Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.